CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 78.1% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
24.34
1.21%
  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
  • Ownership
Trading сonditions
Spread 0.08
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.026151 %
Charges from full value of position ($-4.97)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.026151%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.003929 %
Charges from full value of position ($0.75)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.003929%
Overnight fee time 22:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Xencor Inc ESG Risk Ratings

High Medium Low Negligible

‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats
Prev. Close* 24.05
Open* 23.78
1-Year Change* -30.16%
Day's Range* 23.76 - 24.52
52 wk Range 16.49-38.20
Average Volume (10 days) 566.65K
Average Volume (3 months) 10.87M
Market Cap 1.20B
P/E Ratio -100.00K
Shares Outstanding 60.88M
Revenue 145.26M
EPS -1.99
Dividend (Yield %) N/A
Beta 0.70
Next Earnings Date Feb 21, 2024

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Feb 22, 2024 24.34 0.90 3.84% 23.44 24.52 23.44
Feb 21, 2024 24.05 0.85 3.66% 23.20 24.05 23.05
Feb 20, 2024 23.47 -0.38 -1.59% 23.85 24.80 23.25
Feb 16, 2024 24.12 3.16 15.08% 20.96 24.19 20.76
Feb 15, 2024 21.24 1.15 5.72% 20.09 21.32 20.09
Feb 14, 2024 20.03 0.61 3.14% 19.42 20.05 19.19
Feb 13, 2024 19.09 -0.32 -1.65% 19.41 19.89 18.81
Feb 12, 2024 20.48 1.27 6.61% 19.21 20.55 19.19
Feb 9, 2024 19.40 0.82 4.41% 18.58 19.68 18.58
Feb 8, 2024 18.62 0.27 1.47% 18.35 18.72 18.31
Feb 7, 2024 18.64 -0.30 -1.58% 18.94 18.97 18.42
Feb 6, 2024 19.05 0.72 3.93% 18.33 19.06 18.33
Feb 5, 2024 18.77 0.36 1.96% 18.41 18.91 18.15
Feb 2, 2024 18.71 0.16 0.86% 18.55 18.85 18.29
Feb 1, 2024 19.01 0.31 1.66% 18.70 19.15 18.33
Jan 31, 2024 18.66 -0.43 -2.25% 19.09 19.52 18.53
Jan 30, 2024 19.36 -0.75 -3.73% 20.11 20.18 19.19
Jan 29, 2024 20.46 0.59 2.97% 19.87 20.51 19.64
Jan 26, 2024 20.05 0.61 3.14% 19.44 20.25 19.44
Jan 25, 2024 19.77 0.20 1.02% 19.57 20.20 19.56

Xencor Inc Events

Time (UTC) Country Event
Tuesday, February 27, 2024

Time (UTC)

21:00

Country

US

Event

Q4 2023 Xencor Inc Earnings Release
Q4 2023 Xencor Inc Earnings Release

Forecast

-

Previous

-

Time (UTC)

21:30

Country

US

Event

Q4 2023 Xencor Inc Earnings Call
Q4 2023 Xencor Inc Earnings Call

Forecast

-

Previous

-
Monday, May 6, 2024

Time (UTC)

10:59

Country

US

Event

Q1 2024 Xencor Inc Earnings Release
Q1 2024 Xencor Inc Earnings Release

Forecast

-

Previous

-
View all events
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total revenue 164.579 275.111 122.694 156.7 40.603
Revenue 164.579 275.111 122.694 156.7 40.603
Total Operating Expense 247.152 232.144 199.491 142.876 119.973
Selling/General/Admin. Expenses, Total 47.489 38.837 29.689 24.286 22.472
Research & Development 199.563 192.507 169.802 118.59 97.501
Operating Income -82.573 42.967 -76.797 13.824 -79.37
Interest Income (Expense), Net Non-Operating 28.251 40.138 7.264 13.619 9.086
Other, Net -0.186 -0.474 0.2 -0.256 -0.125
Net Income Before Taxes -54.508 82.631 -69.333 27.187 -70.409
Net Income After Taxes -55.181 82.631 -69.333 26.875 -70.409
Net Income Before Extra. Items -55.181 82.631 -69.333 26.875 -70.409
Total Extraordinary Items 0
Net Income -55.181 82.631 -69.333 26.875 -70.409
Income Available to Common Excl. Extra. Items -55.181 82.631 -69.333 26.875 -70.409
Income Available to Common Incl. Extra. Items -55.181 82.631 -69.333 26.875 -70.409
Diluted Net Income -55.181 82.631 -69.333 26.875 -70.409
Diluted Weighted Average Shares 59.6525 60.4955 57.2127 58.4679 53.9421
Diluted EPS Excluding Extraordinary Items -0.92504 1.3659 -1.21185 0.45965 -1.30527
Diluted Normalized EPS -0.92395 1.37913 -1.21185 0.45965 -1.30527
Unusual Expense (Income) 0.1 0.8
Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
Total revenue 45.523 18.962 21.61 27.299 30.175
Revenue 45.523 18.962 21.61 27.299 30.175
Total Operating Expense 71.52 78.327 64.303 65.647 58.175
Selling/General/Admin. Expenses, Total 11.46 13.948 12.751 12.374 11.091
Research & Development 60.06 64.379 51.452 53.273 47.084
Operating Income -25.997 -59.365 -42.693 -38.348 -28
Interest Income (Expense), Net Non-Operating 4.052 -0.006 30.178 6.678 -5.828
Other, Net -0.009 -1.392 0.058 -0.001 -0.147
Net Income Before Taxes -21.954 -60.763 -12.457 -31.671 -33.975
Net Income After Taxes -21.954 -60.763 -12.042 -32.759 -33.975
Net Income Before Extra. Items -21.954 -60.763 -12.042 -32.759 -33.975
Net Income -21.954 -60.763 -12.042 -32.759 -33.975
Income Available to Common Excl. Extra. Items -21.954 -60.763 -12.042 -32.759 -33.975
Income Available to Common Incl. Extra. Items -21.954 -60.763 -12.042 -32.759 -33.975
Diluted Net Income -21.954 -60.763 -12.042 -32.759 -33.975
Diluted Weighted Average Shares 59.8076 59.7717 59.9149 59.7166 59.5671
Diluted EPS Excluding Extraordinary Items -0.36708 -1.01659 -0.20099 -0.54857 -0.57036
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS -0.36206 -1.01659 -0.1999 -0.54857 -0.57036
Unusual Expense (Income) 0.1
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total Current Assets 675.342 424.368 637.672 558.405 315.727
Cash and Short Term Investments 623.062 334.107 603.003 529.782 294.361
Cash & Equivalents 53.942 143.48 163.544 50.312 26.246
Short Term Investments 569.12 190.627 439.459 479.47 268.115
Total Receivables, Net 28.997 66.384 23.943 22.076 10.991
Accounts Receivable - Trade, Net 28.997 66.384 23.943 21.574 10.187
Prepaid Expenses 23.283 23.877 10.726 6.547 10.375
Total Assets 846.266 838.211 703.244 670.25 576.732
Property/Plant/Equipment, Total - Net 93.602 59.97 32.282 25.185 11.813
Property/Plant/Equipment, Total - Gross 121.891 82.798 49.313 37.79 21.239
Accumulated Depreciation, Total -28.289 -22.828 -17.031 -12.605 -9.426
Intangibles, Net 18.5 16.493 15.977 14.421 11.969
Long Term Investments 58.209 331.727 17.101 71.526 236.108
Note Receivable - Long Term 0 5 0.402 0.804
Other Long Term Assets, Total 0.613 0.653 0.212 0.311 0.311
Total Current Liabilities 63.844 70.738 121.061 66.558 53.853
Accounts Payable 10.088 14.001 8.954 10.189 3.797
Accrued Expenses 23.436 19.443 19.492 11.164 9.662
Notes Payable/Short Term Debt 0 0 0 0 0
Other Current Liabilities, Total 30.32 37.294 92.615 45.205 40.394
Total Liabilities 118.77 104.707 130.8 77.049 55.051
Total Long Term Debt 0 0 0 0 0
Other Liabilities, Total 54.926 33.969 9.739 10.491 1.198
Total Equity 727.496 733.504 572.444 593.201 521.681
Preferred Stock - Non Redeemable, Net 0 0 0 0
Common Stock 0.601 0.595 0.58 0.569 0.563
Additional Paid-In Capital 1072.13 1017.52 937.525 887.873 845.366
Retained Earnings (Accumulated Deficit) -338.285 -283.104 -365.735 -296.402 -323.277
Other Equity, Total -6.952 -1.51 0.074 1.161 -0.971
Total Liabilities & Shareholders’ Equity 846.266 838.211 703.244 670.25 576.732
Total Common Shares Outstanding 59.9977 59.3556 57.8734 56.9023 56.2795
Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
Total Current Assets 571.176 593.562 629.976 675.342 667.998
Cash and Short Term Investments 494.532 551.372 588.022 623.062 600.236
Cash & Equivalents 52.733 34.71 72.394 53.942 52.654
Short Term Investments 441.799 516.662 515.628 569.12 547.582
Total Receivables, Net 55 20.019 19.861 28.997 44.876
Accounts Receivable - Trade, Net 55 20.019 19.861 28.997 44.876
Prepaid Expenses 21.644 22.171 22.093 23.283 22.886
Total Assets 778.43 778.121 803.411 846.266 835.269
Property/Plant/Equipment, Total - Net 102.842 101.043 100.382 93.602 70.72
Intangibles, Net 18.744 18.708 18.244 18.5 18.094
Long Term Investments 84.63 64.21 54.21 58.209 72.844
Other Long Term Assets, Total 1.038 0.598 0.599 0.613 0.613
Total Current Liabilities 53.041 44.63 65.056 63.844 90.032
Accounts Payable 14.967 14.097 15.341 10.088 14.618
Accrued Expenses 28.852 22.668 19.611 23.436 39.84
Notes Payable/Short Term Debt 0 0 0 0 0
Other Current Liabilities, Total 9.222 7.865 30.104 30.32 35.574
Total Liabilities 109.42 99.245 119.828 118.77 112.571
Total Long Term Debt 0 0 0 0 0
Other Liabilities, Total 56.379 54.615 54.772 54.926 22.539
Total Equity 669.01 678.876 683.583 727.496 722.698
Common Stock 0.607 0.607 0.605 0.601 0.598
Additional Paid-In Capital 1114.38 1101.13 1085.65 1072.13 1058.22
Retained Earnings (Accumulated Deficit) -445.271 -421.002 -399.048 -338.285 -326.244
Other Equity, Total -0.709 -1.86 -3.625 -6.952 -9.875
Total Liabilities & Shareholders’ Equity 778.43 778.121 803.411 846.266 835.269
Total Common Shares Outstanding 60.6659 60.6001 60.3816 59.9977 59.7733
Preferred Stock - Non Redeemable, Net 0 0 0 0 0
Note Receivable - Long Term 0 0 5
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Net income/Starting Line -55.181 82.631 -69.333 26.875 -70.409
Cash From Operating Activities 24.485 -16.853 -5.004 64.374 -79.756
Cash From Operating Activities 8.799 7.491 5.794 4.298 3.251
Non-Cash Items 22.002 -4.374 10.358 27.759 20.569
Cash Taxes Paid 0.7 0 0 0.4 0.233
Changes in Working Capital 48.865 -102.601 48.177 5.442 -33.167
Cash From Investing Activities -119.725 -46.249 100.192 -50.97 -164.767
Capital Expenditures -43.404 -15.981 -13.768 -11.038 -9.147
Other Investing Cash Flow Items, Total -76.321 -30.268 113.96 -39.932 -155.62
Cash From Financing Activities 5.702 43.038 18.044 10.662 254.241
Financing Cash Flow Items 0 -14.741
Issuance (Retirement) of Stock, Net 5.702 43.038 18.044 10.662 268.982
Net Change in Cash -89.538 -20.064 113.232 24.066 9.718
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Net income/Starting Line -60.763 -55.181 -43.139 -10.38 23.594
Cash From Operating Activities -30.614 24.485 48.916 50.084 5.815
Cash From Operating Activities 2.245 8.799 6.64 4.402 2.178
Non-Cash Items 15.536 22.002 43.354 35.66 15.205
Changes in Working Capital 12.368 48.865 42.061 20.402 -35.162
Cash From Investing Activities 48.144 -119.725 -144.273 -147.398 -71.759
Capital Expenditures -11.19 -43.404 -32.505 -17.64 -2.995
Other Investing Cash Flow Items, Total 59.334 -76.321 -111.768 -129.758 -68.764
Cash From Financing Activities 0.922 5.702 4.531 3.244 0.731
Issuance (Retirement) of Stock, Net 0.922 5.702 4.531 3.244 0.731
Net Change in Cash 18.452 -89.538 -90.826 -94.07 -65.213
Cash Taxes Paid 0.7 0.072
Investor Name Investor Type Percent Outstanding Shares Held Shares change Holdings Date Turnover Rating
BlackRock Institutional Trust Company, N.A. Investment Advisor 15.488 9387804 -162135 2023-06-30 LOW
PRIMECAP Management Company Investment Advisor 12.7874 7750852 188033 2023-06-30
The Vanguard Group, Inc. Investment Advisor/Hedge Fund 10.969 6648648 -29965 2023-06-30 LOW
EcoR1 Capital, LLC Hedge Fund 8.7151 5282516 0 2023-06-30 LOW
T. Rowe Price Investment Management, Inc. Investment Advisor 6.216 3767742 -13597 2023-06-30 LOW
Fidelity Management & Research Company LLC Investment Advisor 5.4213 3286013 -122139 2023-06-30 LOW
State Street Global Advisors (US) Investment Advisor/Hedge Fund 5.1203 3103577 -176591 2023-06-30 LOW
T. Rowe Price Associates, Inc. Investment Advisor 5.0137 3038962 -133361 2023-06-30 LOW
Loomis, Sayles & Company, L.P. Investment Advisor/Hedge Fund 3.1484 1908358 -39311 2023-06-30 LOW
Dimensional Fund Advisors, L.P. Investment Advisor/Hedge Fund 2.6038 1578246 29585 2023-06-30 LOW
Geode Capital Management, L.L.C. Investment Advisor/Hedge Fund 1.9971 1210491 50808 2023-06-30 LOW
Armistice Capital LLC Hedge Fund 1.4716 892000 56000 2023-06-30 MED
Johnson & Johnson Innovation-JJDC, Inc. Venture Capital 1.2342 748062 0 2023-06-30 LOW
Candriam Belgium S.A. Investment Advisor/Hedge Fund 1.0773 652984 -45435 2023-06-30 LOW
Candriam Luxembourg S.A. Investment Advisor 1.0773 652965 0 2023-09-30 MED
Northern Trust Investments, Inc. Investment Advisor/Hedge Fund 0.8994 545157 11369 2023-06-30 LOW
Norges Bank Investment Management (NBIM) Sovereign Wealth Fund 0.8892 538945 -36100 2022-12-31 LOW
JP Morgan Asset Management Investment Advisor 0.8214 497863 54206 2023-06-30 LOW
Invesco Capital Management LLC Investment Advisor 0.8033 486877 16153 2023-06-30 LOW
Charles Schwab Investment Management, Inc. Investment Advisor 0.7888 478101 3683 2023-06-30 LOW

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Xencor Inc Company profile

About Xencor Inc

Xencor, Inc. is a clinical-stage biopharmaceutical company that is focused on discovering and developing engineered monoclonal antibodies and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The Company is advancing a portfolio of clinical-stage XmAb drug candidates from its protein engineering technology platforms. The Company uses its engineering capabilities to enable its understanding of protein structure and interactions to design technologies and XmAb development candidates with properties. It is focused on the Fc domain, which is the part of an antibody that interacts with various segments of the immune system and controls antibody structure. The Fc domain is constant and interchangeable among antibodies, and its engineered Fc domains are the XmAb technology, which can be readily substituted for natural Fc domains. Its drug candidates include Plamotamab, XmAb717, Tidutamab, XmAb841, XmAb306, AMG 509, XmAb819, XmAb104, XmAb564 and Novartis XmAb.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Xencor Inc revenues increased from $122.7M to $275.1M. Net income totaled $82.6M vs. loss of $69.3M. Revenues reflect Research collaboration segment increase from $4.5M to $93M, Royalties segment increase from $17.8M to $80.3M. Basic Earnings per Share excluding Extraordinary Items increased from -$1.21 to $1.42.

Equity composition

Common Stock $0.01 Par, 12/13, 200M auth., 29,422,576 issd., Insiders own approx. 56.73%

Industry: Bio Therapeutic Drugs

465 N. Halstead St.
Suite 200
PASADENA
CALIFORNIA 91107
US

Income Statement

  • Annual
  • Quarterly

News

Nvidia (NVDA) confronts high expectations for Q4 results

Nvidia is arguably the hottest company on the planet. The company reports its Q4 results after the closing bell on Wednesday, the 21st of February. We preview what to expect from Nvidia’s earnings and analyse the technicals of its stock price.

12:13, 20 February 2024

UK Bank Earnings: What to expect from Lloyds, Barclays and HSBC?

UK banks will be in the spotlight in the week ahead as the European earnings season continues

16:38, 16 February 2024

Is Big Tech behind the apparent bull market rally?

While the Magnificent Seven have dominated market momentum in recent months, it’s not true that they are the sole drivers of the recent rally in equity markets.

16:05, 8 February 2024

US Earnings Week Ahead: Walt Disney, Uber, and Pepsi Co.

The last of the Magnificent Seven have reported, delivering mixed results. Meanwhile, according to FactSet, the S&P 500 is set for negative earnings growth for Q4, with estimates for the next quarter also downgraded.

16:24, 2 February 2024

Bank of England preview: will updated projections show more cuts are expected in 2024?

Markets have no doubt that the BoE will keep its rate unchanged

15:43, 31 January 2024

Meta Platforms Q4 earnings forecast to surge on solid ad revenues

Meta Platforms (META) reports its Q4 results after Wall Street’s closing bell on February 1, 2024. We preview what to expect from the results and analyse the stock’s technicals.

15:33, 31 January 2024

Federal Reserve meeting preview: strong data is making it hard to justify cutting rates

Markets expect the Fed to keep rates unchanged as strong economic data continues

11:30, 30 January 2024

People also watch

XRP/USD

0.54 Price
-2.440% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 22:00 (UTC)
Spread 0.01168

Oil - Crude

77.78 Price
-0.640% 1D Chg, %
Long position overnight fee 0.0162%
Short position overnight fee -0.0381%
Overnight fee time 22:00 (UTC)
Spread 0.030

US100

17,973.60 Price
+0.050% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0039%
Overnight fee time 22:00 (UTC)
Spread 1.8

BTC/USD

50,916.50 Price
-1.490% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 22:00 (UTC)
Spread 106.00

Still looking for a broker you can trust?

Join the 580.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading